{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:42:24Z","timestamp":1792176144969,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cpcardiol.2023.102017","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T20:39:21Z","timestamp":1691267961000},"page":"102017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"PA","title":["Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-9073","authenticated-orcid":false,"given":"Adrija","family":"Hajra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Ujjawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selia","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.102017_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5853\/jos.2019.01970","article-title":"Non-vitamin K antagonist oral anticoagulants in medical conditions at high risk of thromboembolism beyond atrial fibrillation","volume":"21","author":"Hong","year":"2019","journal-title":"J Stroke"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb","year":"2016","journal-title":"Dentist J"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0004","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010\u20132017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0006","first-page":"93","article-title":"Non-vitamin K antagonist oral anticoagulant after acute coronary syndrome: is there a role?","volume":"13","author":"Guedeney","year":"2018","journal-title":"Interv Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.amjcard.2017.10.035","article-title":"Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome","volume":"121","author":"Khan","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0008","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamacardio.2017.5306","article-title":"Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis","volume":"3","author":"Chiarito","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0009","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0010","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0011","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0012","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0013","doi-asserted-by":"crossref","first-page":"27183","DOI":"10.1074\/jbc.272.43.27183","article-title":"Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation","volume":"272","author":"Byzova","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0014","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)02225-X","article-title":"Blood coagulation","volume":"355","author":"Dahlb\u00e4ck","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0015","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/01.CIR.95.10.2380","article-title":"Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm","volume":"95","author":"Held","year":"1997","journal-title":"Circulation"},{"issue":"4 Suppl S","key":"10.1016\/j.cpcardiol.2023.102017_bib0016","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0017","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0018","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2014.07.017","volume":"64","author":"Fihn","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0019","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0021","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006475","article-title":"Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation)","volume":"6","author":"Thomas","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002776","article-title":"Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions","volume":"5","author":"Di Biase","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0024","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.116.024666","volume":"135","author":"Lindner","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0026","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0027","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0028","unstructured":"Canadian edoxaban(lixiana\u00ae) registry in patients with atrial fibrillation\/flutter with confirmed valvular heart disease - full text view (no date) ClinicalTrials.gov. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03488420 Accessed July 10, 2023."},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0029","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/M20-6194","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study","volume":"174","author":"Dawwas","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0031","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0032","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMe1811089","article-title":"COMMANDER HF - a trial and an answer","volume":"379","author":"Pfeffer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0033","first-page":"1250","article-title":"Anticoagulation in heart failure: a review","volume":"8","author":"Zeitler","year":"2015","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0034","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano Robert","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-021-01930-y","article-title":"Anticoagulants for stroke prevention in heart failure with reduced ejection fraction","volume":"111","author":"Sch\u00e4fer","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjmed.2021.07.023","article-title":"An updated review of the efficacy and safety of direct oral anticoagulants in treatment of left ventricular thrombus","volume":"135","author":"Honan","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0037","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0038","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11239-020-02371-6","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus","volume":"52","author":"Bass","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0039","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/ehf2.12718","article-title":"Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus","volume":"7","author":"Iqbal","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cjco.2021.04.007","article-title":"Direct oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: a systematic review and meta-analysis","volume":"3","author":"Michael","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0041","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12872-021-01967-x","article-title":"Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation","volume":"21","author":"Witte","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0042","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.0000000000009443","article-title":"Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the guideline Subcommittee of the American Academy of Neurology","volume":"94","author":"Mess\u00e9","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0043","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.922467","article-title":"Direct oral anticoagulants after percutaneous patent foramen ovale (PFO) closure: a call for caution","volume":"21","author":"Bovin","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0044","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/STROKEAHA.121.037541","article-title":"Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study","volume":"53","author":"Yaghi","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11239-021-02417-3","article-title":"The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0046","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.2174\/1381612825666181226151959","article-title":"Novel oral anticoagulants in peripheral artery disease: current evidence","volume":"24","author":"Koutsoumpelis","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0047","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0048","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0049","series-title":"StatPearls [Internet]","article-title":"Rivaroxaban","author":"Singh","year":"2023"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT registry","volume":"11","author":"Tanawuttiwat","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0052","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1055\/s-0040-1720961","article-title":"Efficacy and safety of oral anticoagulants in patients with systolic heart failure in sinus rhythm: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"4","author":"Nygaard","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0053","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/j.healun.2021.01.1091","article-title":"Safety of direct oral anticoagulants in left ventricular assist device patients","volume":"40","author":"Kos","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0054","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin k antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102017_bib0055","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.jvs.2022.07.087","article-title":"Direct oral anticoagulants versus direct thrombin inhibitors for treatment of acute heparin-induced thrombocytopenia","volume":"76","author":"Pham","year":"2022","journal-title":"J Vasc Surg"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623004346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623004346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:12:07Z","timestamp":1758939127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623004346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0146280623004346"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102017","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"102017"}}